FH

TYAN Upgrades HPC, AI and Data Center Solutions with the Power of 5th Gen Intel® Xeon® Scalable Processors

Retrieved on: 
Thursday, December 14, 2023

Growing and excelling with workload-optimized performance, 5th Gen Intel Xeon delivers more compute power and faster memory within the same power envelope as the previous generation.

Key Points: 
  • Growing and excelling with workload-optimized performance, 5th Gen Intel Xeon delivers more compute power and faster memory within the same power envelope as the previous generation.
  • "By harnessing the capabilities of Intel's new Xeon CPUs, TYAN's 5th-Gen Intel Xeon-supported solutions are designed to handle the intense demands of HPC, data centers, and AI workloads.
  • In addition, TYAN offers Thunder HX FT65T-B7130 , the other deskside HPC platform providing balanced CPU/GPU computing architecture with dual 5th Generation Intel Xeon Scalable processor support.
  • In addition to server systems, TYAN provides upgraded motherboard solutions based on the latest 5th Gen Intel Xeon Scalable processor.

TYAN Upgrades HPC, AI and Data Center Solutions with the Power of 5th Gen Intel® Xeon® Scalable Processors

Retrieved on: 
Thursday, December 14, 2023

Growing and excelling with workload-optimized performance, 5th Gen Intel Xeon delivers more compute power and faster memory within the same power envelope as the previous generation.

Key Points: 
  • Growing and excelling with workload-optimized performance, 5th Gen Intel Xeon delivers more compute power and faster memory within the same power envelope as the previous generation.
  • "By harnessing the capabilities of Intel's new Xeon CPUs, TYAN's 5th-Gen Intel Xeon-supported solutions are designed to handle the intense demands of HPC, data centers, and AI workloads.
  • In addition, TYAN offers Thunder HX FT65T-B7130 , the other deskside HPC platform providing balanced CPU/GPU computing architecture with dual 5th Generation Intel Xeon Scalable processor support.
  • In addition to server systems, TYAN provides upgraded motherboard solutions based on the latest 5th Gen Intel Xeon Scalable processor.

Volvo FH Electric wins 'Truck of the Year 2024' award

Retrieved on: 
Thursday, November 23, 2023

GOTHENBURG, Sweden, Nov. 23, 2023 /PRNewswire/ -- Volvo FH Electric is the winner of the "International Truck of the Year 2024" award. Roger Alm, to the right, accepted the award at a ceremony last night in Lyon, France.

Key Points: 
  • Volvo Trucks has scooped the prestigious industry award for its Volvo FH Electric.
  • GOTHENBURG, Sweden, Nov. 23, 2023 /PRNewswire/ -- Volvo FH Electric is the winner of the "International Truck of the Year 2024" award.
  • "With the introduction of the FH Electric, Volvo Trucks has delivered a state-of-the-art battery electric vehicle range, suitable for a wide array of transport operations.
  • "I am very proud that our Volvo FH Electric has won this highly respected award.

Robotics System Integration Market to grow by USD 4.75 billion from 2022 to 2027, The technological innovations in robotic system integration to drive the growth- Technavio

Retrieved on: 
Saturday, October 28, 2023

NEW YORK, Oct. 27, 2023 /PRNewswire/ -- The robotics system integration market is expected to grow by USD 4.75 billion from 2022 to 2027.

Key Points: 
  • NEW YORK, Oct. 27, 2023 /PRNewswire/ -- The robotics system integration market is expected to grow by USD 4.75 billion from 2022 to 2027.
  • The technological innovations in robotic system integration are key factors driving market growth.
  • A shortage of people with expertise and skills in robotic system integration services is a significant challenge restricting market growth.
  • The robotic injection molding machine market size is estimated to grow at a CAGR of 4.79% between 2022 and 2027.

Kyowa Kirin Presents Real-World Findings at ASBMR Annual Meeting Highlighting Progressive Disease Burden of X-linked Hypophosphatemia (XLH)

Retrieved on: 
Monday, October 16, 2023

Most patients had received some form of conventional therapy for XLH prior to burosumab treatment, with 61% receiving calcitriol and 43% receiving phosphate supplements.

Key Points: 
  • Most patients had received some form of conventional therapy for XLH prior to burosumab treatment, with 61% receiving calcitriol and 43% receiving phosphate supplements.
  • Older patients were under-represented in the study population, limiting the generalizability of the findings to this group.
  • In this retrospective observational cohort study, researchers examined healthcare claims data from the Merative™ MarketScan® Commercial and Medicare Databases.
  • The differences between the study groups were apparent even among young children and persisted throughout a person's life.

The PlanET Biogas Group Celebrates 25 Years in Business!

Retrieved on: 
Friday, October 6, 2023

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20231005515426/en/
    Hendrik Becker, PlanET Biogas Group Shareholder (Left), Jörg Meyer zu Strohe CEO & Shareholder (Middle) and Roland Becker, CFO & Shareholder (Right) pose for a picture at the 25th anniversary celebration.
  • FH), managing director and shareholder of the PlanET Biogas Group welcomed guests and thanked employees for their engagement.
  • Today, PlanET is one of the world leaders in the biogas industry with 700+ biogas plants and 100+ RNG plants worldwide.
  • The highly skilled employees are customer focused and PlanET biogas plants are characterized by reliability, innovation and efficiency.

Peer-Reviewed Independent Study Published in Microbiology Spectrum Finds Cue Health’s Molecular COVID-19 Test is as Accurate as a Lab-Based PCR Test

Retrieved on: 
Wednesday, October 4, 2023

The study, published in Microbiology Spectrum, a journal produced by the American Society for Microbiology, presents findings from a head-to-head comparison of the Cue COVID-19 test against lab-based RT-PCR on paired samples from 3,037 individuals.

Key Points: 
  • The study, published in Microbiology Spectrum, a journal produced by the American Society for Microbiology, presents findings from a head-to-head comparison of the Cue COVID-19 test against lab-based RT-PCR on paired samples from 3,037 individuals.
  • The findings from paired testing revealed a 99.4% match between results from Cue’s test and the reference PCR tests with 100% clinical sensitivity to detect positive cases, yielding no false negatives.
  • To further expand its diagnostic test menu for at-home and point-of-care use, Cue has made a number of other submissions with the FDA.
  • Cue did not provide funding or any other support of the study.

HKTDC Hong Kong Watch Design Competition mixes creativity, playfulness

Retrieved on: 
Friday, September 15, 2023

HONG KONG, Sept 15, 2023 - (ACN Newswire) - Nearly 15,000 buyers from 95 countries and regions attended the physical exhibitions of the 42nd HKTDC Hong Kong Watch & Clock Fair and 11th Salon de TE, organised by the Hong Kong Trade Development Council (HKTDC), Hong Kong Watch Manufacturers Association Ltd and The Federation of Hong Kong Watch Trades & Industries Ltd.

Key Points: 
  • HONG KONG, Sept 15, 2023 - (ACN Newswire) - Nearly 15,000 buyers from 95 countries and regions attended the physical exhibitions of the 42nd HKTDC Hong Kong Watch & Clock Fair and 11th Salon de TE, organised by the Hong Kong Trade Development Council (HKTDC), Hong Kong Watch Manufacturers Association Ltd and The Federation of Hong Kong Watch Trades & Industries Ltd.
  • During the fairs, the results of the 40th Hong Kong Watch Design Competition, also organised by the three organisers, were announced.
  • Open Group champion of the 40th Hong Kong Watch & Clock Design Competition: Scroll Bar.
  • The Hong Kong Watch Design Competition has been striving to elevate the design and quality of Hong Kong watches and clocks and encourage creative ideas, while also identifying local design talent and injecting a new impetus into the industry.

zkMe and QuestN partner to enhance campaign effectiveness with encrypted biometric verification

Retrieved on: 
Saturday, September 9, 2023

This partnership ensures quest givers protection against bot and sybil attacks while protecting the privacy and data security of sensitive user data.

Key Points: 
  • This partnership ensures quest givers protection against bot and sybil attacks while protecting the privacy and data security of sensitive user data.
  • Adhering to their design philosophies - Private-by-design, Secure-by-design, & Decentralized-by-design - zkMe ensures that all data managed by MeID and zkMe products remains completely private.
  • No party, including zkMe, QuestN, or any quest creators, has ever access to the underlying private data, nor is this data stored on the user's device.
  • Addressing the privacy concerns of the web3 community, zkMe ensures a level playing field that is both fair and private, embodying their slogan: "you, privately verified".

LIB Therapeutics and Hasten Biopharmaceutical Company Announce $325 Million Strategic Collaboration to Develop and Commercialize Lerodalcibep in Greater China

Retrieved on: 
Tuesday, September 12, 2023

LIB Therapeutics Inc. (“LIB”) and Hasten Biopharmaceutical Co., Ltd. (“Hasten”), today announce that the companies have entered into an agreement granting Hasten the rights to develop and commercialize lerodalcibep in Greater China (Chinese Mainland, Hong Kong, Macau and Taiwan).

Key Points: 
  • LIB Therapeutics Inc. (“LIB”) and Hasten Biopharmaceutical Co., Ltd. (“Hasten”), today announce that the companies have entered into an agreement granting Hasten the rights to develop and commercialize lerodalcibep in Greater China (Chinese Mainland, Hong Kong, Macau and Taiwan).
  • LIB is a late-stage, biopharmaceutical company developing lerodalcibep for patients at very high and high-risk of cardiovascular disease (CVD).
  • We look forward to working with LIB to bring lerodalcibep to patients in Greater China as soon as possible.”
    Under the terms of the agreement, LIB has granted Hasten the exclusive rights to develop and commercialize lerodalcibep in Greater China.
  • A joint steering committee will be established to ensure alignment of lerodalcibep’s development in Greater China with LIB’s overall global development and commercialization strategy.